Biogen (BIIB) to Acquire Apellis for $5.6 Billion
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowBiogen (BIIB) announced plans to acquire Apellis Pharmaceuticals for $5.6 billion. This acquisition aims to enhance Biogen's portfolio in the neurological disorders market. The transaction is expected to be finalized in the second half of 2024, pending regulatory approvals. This move may increase Biogen's market presence and influence, reflecting its strategy to diversify and grow its offerings post patent expirations of major products.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Biogen Inc. (BIIB)
Biogen is a biotech focused on neurological diseases.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier BIIB news
- Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal
- Biogen Reports Positive Phase 2 Results for Lupus Drug: Potential Market Impact
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
